David J. Webb
About
David J. Webb is a scholar working on Cardiology and Cardiovascular Medicine, Physiology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, David J. Webb has authored 265 papers receiving a total of 15.8k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Cardiology and Cardiovascular Medicine, 52 papers in Physiology and 38 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David J. Webb's work include Blood Pressure and Hypertension Studies (60 papers), Nitric Oxide and Endothelin Effects (40 papers) and Cardiovascular Health and Disease Prevention (34 papers). David J. Webb is often cited by papers focused on Blood Pressure and Hypertension Studies (60 papers), Nitric Oxide and Endothelin Effects (40 papers) and Cardiovascular Health and Disease Prevention (34 papers). David J. Webb collaborates with scholars based in United Kingdom, United States and Netherlands. David J. Webb's co-authors include Ian B. Wilkinson, John R. Cockcroft, James Oliver, David E. Newby, Neeraj Dhaun, Simon Maxwell, Helen MacCallum, Laura Flint, Kenneth Boyd and Robert V. Carlson and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Investigation.
In The Last Decade
David J. Webb
261 papers receiving 15.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| David J. Webb United Kingdom | 61 | 7.4k | 2.9k | 2.1k | 2.0k | 2.0k | 265 | 15.8k | ||
| Jacqueline C.M. Witteman Netherlands | 69 | 5.4k 0.7× | 2.0k 0.7× | 2.3k 1.1× | 2.1k 1.1× | 2.2k 1.1× | 170 | 16.2k | ||
| James H. Stein United States | 61 | 7.6k 1.0× | 2.1k 0.7× | 3.0k 1.5× | 2.8k 1.4× | 4.1k 2.1× | 345 | 18.2k | ||
| Athanase Bénétos France | 73 | 16.0k 2.2× | 3.7k 1.3× | 3.3k 1.6× | 3.0k 1.5× | 2.9k 1.5× | 335 | 23.1k | ||
| Leopoldo Raij United States | 60 | 5.8k 0.8× | 3.7k 1.3× | 1.7k 0.8× | 2.4k 1.2× | 1.7k 0.9× | 202 | 14.6k | ||
| Johan Sundström Sweden | 72 | 6.9k 0.9× | 2.8k 1.0× | 1.2k 0.6× | 3.1k 1.6× | 2.6k 1.3× | 363 | 17.0k | ||
| William H. Frishman United States | 70 | 10.1k 1.4× | 1.8k 0.6× | 1.7k 0.8× | 2.2k 1.1× | 4.3k 2.2× | 921 | 20.6k | ||
| Wendy S. Post United States | 68 | 9.6k 1.3× | 1.4k 0.5× | 2.5k 1.2× | 2.7k 1.4× | 3.4k 1.7× | 436 | 20.1k | ||
| Allan D. Struthers United Kingdom | 75 | 11.0k 1.5× | 2.3k 0.8× | 2.9k 1.4× | 3.9k 2.0× | 3.0k 1.5× | 521 | 19.3k | ||
| Álvaro Alonso United States | 82 | 11.1k 1.5× | 2.6k 0.9× | 2.1k 1.0× | 1.3k 0.6× | 1.8k 0.9× | 587 | 23.1k | ||
| Susan R. Heckbert United States | 75 | 10.0k 1.4× | 1.5k 0.5× | 1.7k 0.8× | 3.8k 1.9× | 2.5k 1.2× | 479 | 21.7k |
Countries citing papers authored by David J. Webb
Since
Specialization
Citations
This map shows the geographic impact of David J. Webb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Webb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Webb more than expected).
Fields of papers citing papers by David J. Webb
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David J. Webb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Webb. The network helps show where David J. Webb may publish in the future.
Co-authorship network of co-authors of David J. Webb
This figure shows the co-authorship network connecting the top 25 collaborators of David J. Webb. A scholar is included among the top collaborators of David J. Webb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Webb. David J. Webb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ranasinghe, Priyanga, et al.. (2025). Knowledge, attitudes, and practices related to hypertension among Sri Lankans: an online cross-sectional survey. BMC Public Health. 25(1). 2376–2376.
2.
MacIntyre, I., Sian Sloan‐Dennison, Benjamin Clark, et al.. (2024). Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP biomarker substudy). Toxicological Sciences. 199(2). 203–209.
3.
Farrah, Tariq E., Dan Pugh, Fiona A. Chapman, et al.. (2023). Choroidal and retinal thinning in chronic kidney disease independently associate with eGFR decline and are modifiable with treatment. Nature Communications. 14(1). 7720–7720.
4.
Addison, Melisande, Priyanga Ranasinghe, & David J. Webb. (2023). Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension. Expert Review of Clinical Pharmacology. 16(11). 1025–1033.
5.
Addison, Melisande, Priyanga Ranasinghe, & David J. Webb. (2023). Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics. Hypertension. 80(11). 2243–2254.
6.
MacIntyre, I., Emma Turtle, Tariq E. Farrah, et al.. (2022). Regular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial. Circulation. 145(6). 416–423.
7.
Ranasinghe, Priyanga, Melisande Addison, James W. Dear, & David J. Webb. (2022). Small interfering RNA: Discovery, pharmacology and clinical development—An introductory review. British Journal of Pharmacology. 180(21). 2697–2720.
8.
Mackenzie, Isla S., Amy Rogers, Neil R Poulter, et al.. (2022). Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. The Lancet. 400(10361). 1417–1425.
9.
Gordon-Keylock, Sabrina, Stanislav Rybtsov, Anahí Binagui-Casas, et al.. (2020). Multi-layered Spatial Transcriptomics Identify Secretory Factors Promoting Human Hematopoietic Stem Cell Development. Cell stem cell. 27(5). 822–839.e8.
10.
Caparrotta, Thomas M., Luke A. K. Blackbourn, Stuart J. McGurnaghan, et al.. (2020). Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland. Diabetes Care. 43(9). 2034–2041.
11.
Ivy, Jessica R., Wilna Oosthuyzen, Robert W. Hunter, et al.. (2016). Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice. Queen Margaret University Publications Repository (Queen Margaret University).
12.
Betz, Boris, Sara Jenks, Andrew D. Cronshaw, et al.. (2016). Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes. Kidney International. 89(5). 1125–1135.
13.
Rorie, David, Amy Rogers, Isla S. Mackenzie, et al.. (2016). Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. BMJ Open. 6(2). e010313–e010313.
14.
Webb, David J.. (2011). THE ROLE OF THE CLINICAL PHARMACOLOGIST IN HEALTH TECHNOLOGY APPRAISAL (HTA). Basic & Clinical Pharmacology & Toxicology. 109. 48–48.
15.
Dhaun, Neeraj, I. MacIntyre, Vanessa Melville, et al.. (2009). Blood Pressure–Independent Reduction in Proteinuria and Arterial Stiffness After Acute Endothelin-A Receptor Antagonism in Chronic Kidney Disease. Hypertension. 54(1). 113–119.
16.
Webb, David J. & Andrew Walker. (2007). Value-based pricing of drugs in the UK. The Lancet. 369(9571). 1415–1416.
17.
Carlson, Robert V., et al.. (2007). The three official language versions of the Declaration of Helsinki: what’s lost in translation?. Journal of Medical Ethics. 33(9). 545–548.
18.
Vérier‐Mine, O., et al.. (2005). Is pregnancy a risk factor for microvascular complications?. UCL Discovery (University College London).
19.
Helmy, Ahmed, Rajiv Jalan, David E. Newby, Peter Hayes, & David J. Webb. (2000). Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology. 118(3). 565–572.
20.
Hodsman, G P, et al.. (1983). Factors related to first dose hypotensive effect of captopril: prediction and treatment.. BMJ. 286(6368). 832–834.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jacqueline C.M. Witteman Breakdown of academic impact, for papers by James H. Stein Breakdown of academic impact, for papers by Athanase Bénétos Breakdown of academic impact, for papers by Leopoldo Raij Breakdown of academic impact, for papers by Johan Sundström Breakdown of academic impact, for papers by William H. Frishman Breakdown of academic impact, for papers by Wendy S. Post Breakdown of academic impact, for papers by Allan D. Struthers Breakdown of academic impact, for papers by Álvaro Alonso Breakdown of academic impact, for papers by Susan R. Heckbert